Clinical trials · Baltimore, MD
Advanced or Metastatic Solid Tumors clinical trials in Baltimore
We’re tracking 316 recruiting advanced or metastatic solid tumors studies with a site in or near Baltimore — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Baltimore
- NCT05208047RecruitingPhase 3
CGT9486 plus sunitinib for advanced gastrointestinal stromal tumors
This trial tests whether adding a new drug called CGT9486 to sunitinib (a standard cancer drug) works better than sunitinib alone for gastrointestinal stromal tumors (GISTs) that have grown or spread. You may qualify if your GIST stopped responding to or caused problems with imatinib, an earlier treatment.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07188896RecruitingPhase 2
Immunotherapy combinations for advanced kidney cancer
This trial tests a combination of immunotherapy drugs (fianlimab, cemiplimab, and possibly ipilimumab) compared to another immunotherapy combo (ipilimumab + nivolumab) for people with advanced kidney cancer who have not had previous treatment. The goal is to see which combination works better.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06422143RecruitingPhase 3
Keytruda with or without Sac-TMT for advanced squamous lung cancer
This trial tests the combination of pembrolizumab (Keytruda) with or without a new drug, sacituzumab tirumotecan (Sac-TMT), as initial treatment for advanced squamous non-small cell lung cancer. It aims to see if adding Sac-TMT after initial treatment helps keep cancer under control longer.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06112314RecruitingPhase 3
New immunotherapy combo for advanced melanoma (first treatment)
This trial tests a new immunotherapy drug (IMC-F106C) combined with standard treatments against the usual nivolumab-based therapy for people with advanced melanoma who have not been treated before. It's for people who carry a specific immune system marker (HLA-A*02:01) and are in fairly good health.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07069712RecruitingPhase 2
New drug combinations before and after surgery for stomach or esophageal cancer
This study tests new drug combinations given before and after surgery for people with stomach or gastroesophageal cancer that can be removed but is locally advanced (has grown into nearby tissue). The goal is to see if these combinations can shrink the tumor and improve outcomes.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07227168RecruitingPhase 1
Study of STRO-004 for advanced solid tumors
This trial tests a new drug called STRO-004 for people with advanced solid tumors (cancers that have spread or come back). It aims to see if the drug is safe and effective for those who have already tried other treatments.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07111520RecruitingPhase 1/Phase 2
Combination treatment for advanced lung cancer
This trial tests two investigational drugs, BNT326 and BNT327, together in people with advanced non-small cell lung cancer (NSCLC) that has spread or can't be cured with local treatment. The goal is to see if the combination is safe and might help shrink tumors.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06526195Recruiting
A study of CardioMEMS and HeartMate 3 for advanced heart failure
This trial tests if a combination of a tiny lung-artery pressure sensor (CardioMEMS) and a mechanical heart pump (HeartMate 3) is safe and effective for people with advanced heart failure. If you qualify, you'll either get the heart pump plus standard medical therapy, or continue with standard therapy alone and have your pressure monitored remotely.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06384807RecruitingPhase 1/Phase 2
Study of BHV-1510 for advanced solid tumors
This trial tests a new drug, BHV-1510, alone or combined with another drug (cemiplimab), for people with advanced solid tumors that haven't responded to other treatments. It's for those who are still in fairly good health and have not had certain prior treatments.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04038502RecruitingPhase 2
Comparing carboplatin and olaparib for prostate cancer with BRCA gene changes
This study compares two treatments for prostate cancer that has spread and has specific gene changes (BRCA or related genes). It aims to see which treatment works better for people whose cancer has stopped responding to other hormone therapies.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04172532RecruitingPhase 1/Phase 2
New targeted drug with radiation for locally advanced pancreatic cancer
This Phase 1/2 trial tests adding peposertib, a targeted anti-cancer drug, to standard radiation for people with locally advanced pancreatic adenocarcinoma. It aims to improve control of the cancer after initial chemotherapy and determine whether the combo is safe and effective.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06545331RecruitingPhase 1
A study of XB010 for advanced solid tumors
This trial tests an investigational drug called XB010 for people with solid tumors that have spread or cannot be removed by surgery. It aims to see if XB010 is safe and effective for several cancer types, including lung, breast, head and neck, and esophageal cancers.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05786924RecruitingPhase 1/Phase 2
Targeted cancer drug study for RAS/RAF mutation-positive tumors
This Phase 1/2 study tests S241656 (a targeted cancer medicine) in people whose cancers have certain “RAS/RAF” gene changes. It may help shrink tumors or control cancer growth, and also finds the safest dose and best way to use the drug.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06203600RecruitingPhase 2/Phase 3
Nivolumab plus standard treatment for advanced stomach or esophageal cancer
This trial tests whether adding the immunotherapy drug nivolumab to standard treatment works better for advanced stomach or esophageal cancer. It is for people whose cancer has already progressed after a first round of chemo plus immunotherapy.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04665739RecruitingPhase 2
Lutetium Lu-177 for lung carcinoid tumors with somatostatin receptors
This trial tests lutetium Lu 177 dotatate, a targeted radiation treatment, for advanced lung neuroendocrine (carcinoid) tumors that have a specific marker called somatostatin receptors. It may help shrink tumors by delivering radiation directly to cancer cells that “light up” on a special scan.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06669117RecruitingPhase 1/Phase 2
VERT-002 for solid tumors with MET changes
This trial tests a new drug, VERT-002, for people with advanced solid tumors, including non-small cell lung cancer (NSCLC), that have specific changes in the MET gene. It aims to see if the drug can shrink tumors or stop them from growing when other treatments haven't worked or aren't available.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07182149RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests a new drug called NRM-823 for people with several types of advanced cancer that have stopped responding to standard treatments. The goal is to see if the drug is safe and how well it works.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06922591RecruitingPhase 1/Phase 2
TNG462 for pancreatic and lung cancer with MTAP loss
This trial tests a new drug called TNG462, alone or combined with other drugs, for people with advanced pancreatic or non-small cell lung cancer whose tumors have a specific genetic change (loss of MTAP and a RAS mutation). It aims to see if TNG462 is safe and works better than current treatments.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07123103RecruitingPhase 1
Study of XB371 for advanced solid tumors
This trial tests a new drug called XB371 for people with advanced solid tumors that have come back or spread. It aims to see if the drug is safe and works against the cancer.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07522073RecruitingPhase 3
Chemotherapy with or without KRAS inhibitor for pancreatic cancer
This study tests whether adding a new drug called INCB161734 to standard chemotherapy helps people with advanced pancreatic cancer that has a specific genetic change (KRAS G12D mutation). You would be randomly assigned to receive either chemotherapy alone or chemotherapy plus the new drug.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06706076RecruitingPhase 1/Phase 2
Experimental pill for lung cancer with EGFR or HER2 changes
This study tests an experimental pill that targets cancer cells with certain gene changes (EGFR or HER2). It may help shrink tumors or slow the cancer's growth in people with advanced non-small cell lung cancer.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06770010Recruiting
Digital brain training for kids with sickle cell disease
This trial is testing a digital program to help improve working memory (the ability to hold and use information in your mind) for children with sickle cell disease. If you join, you'll use a computer-based training program at home and researchers will see if it works and is easy to use.
Washington D.C., District of ColumbiaAges 7–16 - NCT06162221RecruitingPhase 1/Phase 2
Study of RAS inhibitors for advanced RAS-mutated lung cancer
This trial tests new drugs that target specific RAS mutations in advanced non-small cell lung cancer. It's for people whose cancer has a KRAS G12C, G12D, or other RAS mutation and who have already tried standard treatments.
Washington D.C., District of ColumbiaAges 18 years+
Hear when a new Advanced or Metastatic Solid Tumors trial opens near Baltimore, MD
We’ll email you when one opens near Baltimore, MD — at most once a week, no account needed, unsubscribe anytime.
Advanced or Metastatic Solid Tumors trials in other cities
Where these studies are running near Baltimore
Institutions with a site for the recruiting advanced or metastatic solid tumors studies listed above.
- Georgetown University Medical Center · 6 studies
- MedStar Georgetown University Hospital · 3 studies
- Georgetown University · 2 studies
- Sibley Memorial Hospital · 2 studies
- Children's National Hospital
- Exelixis Clinical Site #6
- Georgetown Lombardi Comprehensive Cancer Center
- Georgetown University - Lombardi Comprehensive Cancer Center
What taking part in a advanced or metastatic solid tumors study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting advanced or metastatic solid tumors studies in Maryland.
Common questions
- Are there advanced or metastatic solid tumors clinical trials near Baltimore?
- Yes. We're currently tracking 316 recruiting advanced or metastatic solid tumors studies with a site near Baltimore, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a advanced or metastatic solid tumors study near Baltimore?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Baltimore to take part?
- Not necessarily. These studies have a site near Baltimore, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New advanced or metastatic solid tumors studies open near Baltimore regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.